Dermatology

The Pharmacy Times® Dermatology resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

Ceramide-Containing Cleansers and Moisturizing Creams Plus Corticosteroids Have a Synergistic Treatment Effect For Atopic Dermatitis (Eczema)

Learn More

What can we help you find?

FDA Grants Priority Review to Dupixent for Atopic Dermatitis in Adolescents

If approved for this indication, dupilumab (Dupixent) will be the first systemic biologic medicine to treat adolescents with moderate-to-severe atopic dermatitis.

Psoriasis Drug Ilumya Launches in United States

Sun Pharma announced the availability of its treatment for moderate-to-severe plaque psoriasis in the United States.

Psoriasis Drug Ilumya Now Available in United States

Tildrakizumab-asmn (Ilumya) is indicated for the treatment of moderate-to-severe plaque psoriasis in adults.

Drug Treatment for Psoriasis Now Available in United States

Tildrakizumab-asmn (Ilumya), an injectable interleukin-23 (IL-23) inhibitor, was approved by the FDA in March for adults who are candidates for systemic therapy or phototherapy.

Top news of the day from across the health care landscape.

Dupixent Improves Symptoms, Quality of Life in Adolescents with Atopic Dermatitis

Phase 3 trial results for dupilumab (Dupixent) demonstrate improvement in skin clearing, itch, and certain quality of life measurements for adolescents with atopic dermatitis.

ICER Report Highlights Efficacy and Value of Targeted Therapies for Plaque Psoriasis

In its latest report, the Institute for Clinical and Economic Review (ICER) evaluated the efficacy and value of newer targeted agents that treat moderate-to-severe plaque psoriasis compared with non-targeted therapies.

Plaque Psoriasis Medications May Trigger IBD

Severe Psoriasis Is Linked to Early Death

Patients whose psoriasis covers a large percentage of their body face a significantly higher risk of death than those who do not have the disease, according to results of a recent study.

First Label Update to Include Data on Psoriasis Involving the Genital Area is Approved by FDA

The FDA has approved an updated label for Eli Lilly’s ixekizumab (Taltz) injection 80 mg/mL to include data in psoriasis involving the genital area.

AbbVie Seeks Approval for Moderate to Severe Plaque Psoriasis Drug

Risankizumab shows promise as an important treatment option for people living with plaque psoriasis.

FDA Approves Treatment for Moderate-to-Severe Plaque Psoriasis

The FDA has approved ILUMYA (tildrakizumab-asmn, Sun Pharma) for treating adults with moderate-to-severe plaque psoriasis.

The Pharmacy Times® Dermatology resource center provides a source of all the latest clinical information, with articles covering updates from the robust pipeline of novel therapies for the skin, hair, nails, and mucous membranes, as well as the newest data from all phases of clinical trials and studies in the space. It serves as a hub of information and news for dermatologists everywhere.

Among its other resources are a wealth of videos including interviews with thought leaders and experts in dermatology, and moderated panel discussions about the best practices and key methods for treating complex cases of acne, eczema, dermatitis, and dry or sweaty skin.